SeraCare Leads HIV Grant
Milford-based SeraCare Life Sciences has received just under $300,000 from the federal National Institutes of Health to develop methods of better tracking HIV infections in given populations.
The company will use the $299,771 to develop HIV incidence panels, which are a series of plasma samples from infected patients that researchers can use to determine how recent HIV infections occurred. The company will also collaborate with Boston-based Immunetics Inc. to develop a rapid HIV incidence test using the panels.
The goal of the grant is to more accurately determine the number of new HIV infections in a population, which has been an obstacle to effective monitoring of the epidemic and for evaluating interventions, SeraCare said. Essentially, it is sometimes difficult to determine if an infection is new or old.
“Accurate estimates of the incidence of new HIV infections are critical to every policy decision regarding how to manage and respond to the HIV epidemic,” said Patricia Garrett, senior director of science and technology for SeraCare and principal investigator on the NIH grant.
WBJ Web Partners
Most Recent
Most Recent
0 Comments